Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

cating that the early increase in flares was transient

in this treatment arm before returning to the placebo level.

The reduction of gout flares, by approximately 40%, in the every two-

week dosing arm of these randomized, controlled, clinical trials is

believed to be the first time a urate lowering therapy has demonstrated

a reduction of gout flares versus a placebo.

New results presented from the GOUT 3 study show that for patients who

have been treated with pegloticase continuously for at least 12

months, the frequency of gout flares was reduced to approximately 0.2

flares per three months in the pegloticase every two weeks group, and

0.4 flares per 3 months in the every four weeks group. This represents

a 9-fold and 4-fold reduction in the frequency of gout flares after 12

months of continuous therapy for the every two and every four weeks

groups compared to the flare frequency reported prior to study entry.

Patients and their physicians participating in GOUT 3 study view this

reduction in gout flare frequency as an important clinical benefit and

the Company believes this benefit contributes to their joint decision

to continue therapy.

-- Immunology: The Company previously reported on the immune response to

pegloticase treatment in the GOUT 1 and GOUT 2 studies, showing a high

rate of seroconversion. The presence of anti-pegloticase antibodies

was predictive of a loss of uric acid control and a greater increase in

the risk of infusion reactions, but not a greater severity of infusion

reactions, particularly in the subset of patients with the highest one-

third of antibody titer.

Results of the GOUT 3 study reported confirm that for patients treated

with pegloticase for up to 12 months showed that:

- The overwhelming m
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... VIEW, Calif., May 5 ChemoCentryx, Inc., today ... small molecule antagonist of the C5a receptor, CCX168, ... acceptance of the molecule as a development candidate ... alliance with GlaxoSmithKline (NYSE: GSK ). ...
... May 5 UV germicidal lamps have been used ... airborne respiratory illnesses in schools and hospitals since the ... in Mexican schools during a 1955 Mumps epidemic and ... York that same year. More recently, UVGI units were ...
... Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides an ... Worldwide Sales and Distribution Update, - ... of two, additional marketing and ... recognized backgrounds in the nutraceutical and functional food, ...
Cached Biology Technology:ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4Swine Flu Fears Generate Interest in UV Disinfection Technologies...Again 2Neptune Product and Distribution Update 2Neptune Product and Distribution Update 3Neptune Product and Distribution Update 4
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... , April 26 , , , ... WHO: Written by Evelina Fernandez . Directed by ... , , WHERE: Los Angeles Theatre Center, ... , , WHEN: Previews April 29 ...
... April 26 Northrop Grumman Corporation (NYSE: NOC ), announced ... a search that also included the state of Maryland and the ... , , ... our new corporate office.  Virginia, Maryland and the District put forward ...
... SUNNYVALE, Calif. , April 26 Innovalight, Inc., a ... cell materials and technology, today announced that the company has achieved ... processed solar cells. The conversion efficiency of a solar cell is ... energy. , , , ...
Cached Biology News:Latino Theater Company Presents 'Dementia' Starting April 29 2Northrop Grumman Selects Virginia for New Corporate Office 2Northrop Grumman Selects Virginia for New Corporate Office 3Innovalight Establishes New Record With Silicon Ink Solar Cells 2Innovalight Establishes New Record With Silicon Ink Solar Cells 3
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... Gel extraction kit, 100 preps Storage: The kit ... For longer storage, keep all contents of the ... column purification kit utilizes a silica-gel based membrane ... fragments in the presence of specialized binding buffers. ...
Biology Products: